ES2152920T3 - Composiciones receptoras de retinoides y metodos. - Google Patents

Composiciones receptoras de retinoides y metodos.

Info

Publication number
ES2152920T3
ES2152920T3 ES91905013T ES91905013T ES2152920T3 ES 2152920 T3 ES2152920 T3 ES 2152920T3 ES 91905013 T ES91905013 T ES 91905013T ES 91905013 T ES91905013 T ES 91905013T ES 2152920 T3 ES2152920 T3 ES 2152920T3
Authority
ES
Spain
Prior art keywords
receptors
novel
compounds
transformed
expression vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91905013T
Other languages
English (en)
Inventor
David John Mangelsdorf
Ronald Mark Evans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23898398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2152920(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Application granted granted Critical
Publication of ES2152920T3 publication Critical patent/ES2152920T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/001Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/75Vector systems having a special element relevant for transcription from invertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS POLIPEPTIDOS RECEPTORES, QUE, BAJO LA INTERACCION CON CIERTOS LIGANTES, O LA ACTIVACION POR MEDIO DE CIERTOS COMPUESTOS, MODULAN LA TRANSCRIPCION DE CIERTOS GENES MEDIANTE LA UNION PARA EL COGNADO DE ELEMENTOS DE RESPUESTA ASOCIADOS CON PROMOTORES DE TALES GENES. LOS NUEVOS RECEPTORES DE LA INVENCION MODULAN LA TRANSCRIPCION EN LA PRESENCIA DE COMPUESTOS DE RETINOIDE. LOS RECEPTORES DE LA PRESENTE INVENCION DIFIEREN SIGNIFICATIVAMENTE DE LOS RECEPTORES DE ACIDO RETINOIDE CONOCIDOS, EN SECUENCIA PRIMARIA DE PROTEINA Y EN RESPUESTA A LA EXPOSICION A VARIOS RETINOIDES. LA INVENCION PROPORCIONA ADNS QUE DECODIFICAN LOS NUEVOS RECEPTORES, VECTORES DE EXPRESION PARA LA EXPRESION DE LOS RECEPTORES, CELULAS TRANSFORMADAS CON TALES VECTORES DE EXPRESION, CELULAS COTRANSFORMADAS CON TALES VECTORES DE EXPRESION Y CON VECTORES INFORMADORES PARA CONTROLAR LA MODULACION DE LA TRANSCRIPCION POR LOS RECEPTORES, Y METODOS DE UTILIZAR TALES CELULAS COTRANSFORMADAS ENLA DEPURACION DE LOS COMPUESTOS QUE PUEDEN, DIRECTA O INDIRECTAMENTE, ACTIVAR LOS RECEPTORES. LA INVENCION TAMBIEN PROPORCIONA ENSAYOS DE ACIDO NUCLEICO PARA LA IDENTIFICACION DE LOS ADN QUE DECODIFICAN LOS RECEPTORES RETINOIDES ADICIONALES DE LA MISMA CLASE ASI COMO LOS NUEVOS RECEPTORES DESCRITOS EN EL MISMO.
ES91905013T 1990-02-09 1991-01-22 Composiciones receptoras de retinoides y metodos. Expired - Lifetime ES2152920T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47807190A 1990-02-09 1990-02-09

Publications (1)

Publication Number Publication Date
ES2152920T3 true ES2152920T3 (es) 2001-02-16

Family

ID=23898398

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91905013T Expired - Lifetime ES2152920T3 (es) 1990-02-09 1991-01-22 Composiciones receptoras de retinoides y metodos.

Country Status (9)

Country Link
US (2) US5723329A (es)
EP (2) EP0999271A3 (es)
JP (1) JPH05504479A (es)
AT (1) ATE196310T1 (es)
AU (2) AU654270B2 (es)
CA (1) CA2075182C (es)
DE (1) DE69132411T2 (es)
ES (1) ES2152920T3 (es)
WO (1) WO1991012258A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091518A (en) * 1989-11-16 1992-02-25 The Salk Institute For Biological Studies Beta retinoic acid response elements compositions and assays
CA2075182C (en) 1990-02-09 2003-03-25 David J. Mangelsdorf Retinoid receptor compositions and methods
AU655417B2 (en) * 1990-03-22 1994-12-22 Salk Institute For Biological Studies, The Insect retinoid receptor compositions and methods
WO1993006215A1 (en) * 1991-09-17 1993-04-01 The Salk Institute For Biological Studies Receptor of the thyroid/steroid hormone receptor superfamily
US7098310B1 (en) 1991-12-24 2006-08-29 Ligand Pharmaceuticals Heterodimers of retinoid X receptors (RXRS) and other steroid hormone receptors
US5756448A (en) * 1992-02-26 1998-05-26 The General Hospital Corporation Constitute activator of retinoid (CAR) receptor polypeptides
US6989242B1 (en) 1992-02-26 2006-01-24 The General Hospital Coporation Car receptors and related molecules and methods
GB9206874D0 (en) * 1992-03-30 1992-05-13 Connaught Lab Generation of improved inducible mammalian expression vectors
EP0769023A4 (en) * 1994-06-24 1999-05-26 Human Genome Sciences Inc EPSILON RETINOIC ACID RECEPTOR
US5877018A (en) * 1994-10-20 1999-03-02 Connaught Laboratories Limited Synthetic eukaryotic promoters containing two inducible elements
WO1996023070A2 (en) * 1995-01-23 1996-08-01 Ligand Pharmaceuticals Incorporated HUMAN RETINOID X RECEPTOR - GAMMA (hRXR-GAMMA)
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
JPH11500922A (ja) * 1995-03-03 1999-01-26 ノバルティス・アクチエンゲゼルシャフト 化学リガンドの存在下での受容体媒介トランス活性化による植物における遺伝子発現の制御
KR19990064155A (ko) 1995-10-10 1999-07-26 더블류. 하링, 지. 보이롤 수용체 매개된 트랜스활성화에 의해 식물에서 유전자 발현을조절하기 위한 화학적 리간드로서의유충 호르몬 또는 이의효능제
US6893830B1 (en) 1996-09-27 2005-05-17 The Board Of Regents Of The University Of Texas System Method of screening oxysterol activation of LXRα
US6489451B1 (en) 1997-04-10 2002-12-03 Hefei-Siu-Fung Ustc Pharmaceutical Co., Ltd. Antithrombosis enzyme from the snake venom of agkistrodon acutus
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
AU9036198A (en) * 1997-08-26 1999-03-16 Ariad Gene Therapeutics, Inc. Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain
US6479653B1 (en) 1997-08-26 2002-11-12 Ariad Gene Therapeutics, Inc. Compositions and method for regulation of transcription
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20040033600A1 (en) * 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
US8105825B2 (en) * 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
AU2002251724B2 (en) 2000-10-24 2007-06-21 Syngenta Participations Ag Control of gene expression in plants
US9249207B2 (en) 2001-02-20 2016-02-02 Intrexon Corporation Substitution mutant receptors and their use in an ecdysone receptor-based inducible gene expression system
EP1373470B1 (en) 2001-02-20 2013-04-24 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
WO2002066613A2 (en) 2001-02-20 2002-08-29 Rheogene Holdings, Inc Novel ecdysone receptor/invertebrate retinoid x receptor-based inducible gene expression system
AU2002247214B2 (en) * 2001-02-20 2008-04-03 Intrexon Corporation Chimeric retinoid X receptors and their use in a novel ecdysone receptor-based inducible gene expression system
DE10244149A1 (de) * 2001-09-25 2003-04-30 Werner Keber Verfahren und Einrichtung zum Verhindern einer unzulässigen Flugannäherung von Flugzeugen an zu schützende Bodenobjeke
MXPA04002808A (es) * 2001-09-26 2005-06-06 Rheogene Holdings Inc Acidos nucleicos receptores de ecdisona de mosca blanca, polipeptidos, y sus usos.
US7563879B2 (en) * 2001-09-26 2009-07-21 Intrexon Corporation Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
US20030170724A1 (en) * 2002-03-08 2003-09-11 Anderson David C. Methods of identifying target polypeptides
US20050203283A1 (en) * 2002-03-25 2005-09-15 Fujisawa Pharmaceutical Co., Ltd ISOFORMS OF NUCLEAR RECEPTOR RXR a
US7304161B2 (en) * 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
EA016083B1 (ru) 2005-08-09 2012-02-28 Займоджинетикс, Инк. СПОСОБ ЛЕЧЕНИЯ НЕХОДЖКИНСКОЙ ЛИМФОМЫ С ПОМОЩЬЮ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
CN101489573B (zh) 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
WO2014144380A1 (en) 2013-03-15 2014-09-18 Intrexon Corporation Boron-containing diacylhydrazines
CA2961738A1 (en) 2014-09-17 2016-03-24 Intrexon Corporation Boron-containing diacylhydrazine compounds
US10510304B2 (en) 2016-08-10 2019-12-17 Manufacturing Resources International, Inc. Dynamic dimming LED backlight for LCD array
EP3612210A4 (en) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System IMMUNE CELLS EXPRESSING MODIFIED ANTIGEN RECEPTORS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2603280B1 (fr) * 1986-08-29 1988-10-28 Cird Nouveau compose marque au tritium, sa preparation et son application notamment dans la determination de l'affinite des retinoides pour leur recepteur cellulaire
US5274077A (en) * 1987-12-02 1993-12-28 The Salk Institute For Biological Studies Retinoic acid receptor composition
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5171671A (en) * 1987-12-02 1992-12-15 The Salk Institute For Biological Studies Retinoic acid receptor composition
US5571692A (en) * 1987-12-02 1996-11-05 The Salk Institute For Biological Studies Retinoic acid receptor α, vectors and cells comprising the same DNA encoding
US5260432A (en) * 1989-06-22 1993-11-09 Sloan-Kettering Institute For Cancer Research Human gamma retinoic acid receptor DNA
US5403925A (en) * 1989-12-13 1995-04-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleic acids encoding mammalian H-2RIIBP or RXR.sub.β and uses thereof
CA2075182C (en) 1990-02-09 2003-03-25 David J. Mangelsdorf Retinoid receptor compositions and methods
WO1993006215A1 (en) * 1991-09-17 1993-04-01 The Salk Institute For Biological Studies Receptor of the thyroid/steroid hormone receptor superfamily
JPH06510206A (ja) * 1992-01-24 1994-11-17 アンスティテュー・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル 新規ヘテロダイマー核レセプタータンパク質、それをコードする遺伝子、およびその使用

Also Published As

Publication number Publication date
EP0999271A3 (en) 2003-04-02
DE69132411D1 (de) 2000-10-19
WO1991012258A1 (en) 1991-08-22
ATE196310T1 (de) 2000-09-15
US7501487B1 (en) 2009-03-10
CA2075182C (en) 2003-03-25
EP0999271A2 (en) 2000-05-10
DE69132411T2 (de) 2001-06-07
AU1155395A (en) 1995-05-25
EP0514488B1 (en) 2000-09-13
AU680575B2 (en) 1997-07-31
US5723329A (en) 1998-03-03
CA2075182A1 (en) 1991-08-10
EP0514488A4 (en) 1993-02-17
JPH05504479A (ja) 1993-07-15
AU654270B2 (en) 1994-11-03
EP0514488A1 (en) 1992-11-25
AU7338391A (en) 1991-09-03

Similar Documents

Publication Publication Date Title
ES2152920T3 (es) Composiciones receptoras de retinoides y metodos.
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
Sorensen et al. Identification of the interleukin-3 receptor using an iodinatable, cleavable, photoreactive cross-linking agent.
DK1012274T4 (da) Dødsdomæneholdig receptor-4 (DR4: dødsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L)
NL300043I1 (nl) Middelen voor het moduleren van processen die worden verzorgd door retonoïde receptoren en verbindingen die daarvoor nuttig zijn.
NO982794L (no) Diagnostisering og behandling av AUR-1 og/eller AUR-2 relaterte lidelser
ATE271606T1 (de) Die aktivierung von rezeptoren durch gas6
ATE247667T1 (de) Gdnf-rezeptor und dessen verwendung
DK0542830T3 (da) Analysemetoder og sammensætninger til detektering og evaluering af den intracellulære transduktion af et ekstracellulært signal
NO2010021I1 (no) Denosumab
DE69317883D1 (de) Neue Sieben-Transmembran-Rezeptor V28
ATE266671T1 (de) Nukleinsäuresynthese unter verwendung von mittels licht abspaltbaren schutzgruppen
DE69029812D1 (de) Elemente für retinsäureantwortzusammensetzung und nachweisverfahren
ATE263836T1 (de) Chimere proteine, welche borrelia polypeptide beinhalten, verwendungen dafür
EP1517144A3 (en) Method of identifying an antibody binding to and modulating the activity of a human vanilloid receptor
ATE234859T1 (de) Peptid-derivat
DE69426076D1 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
IL130954A0 (en) Neurturin receptor
DE69231689D1 (de) Zusammensetzung von antwortelementen und ihre verwendung als proben
SE9701010D0 (sv) Antibody
DK0958351T3 (da) Chimere målmolekyler med regulerbar aktivitet
ATE368750T1 (de) Screening-verfahren zum identifizieren von g- proteinen und anderen verbindungen,die die phosphodiesterase (pde)-aktivität beeinflussen
Chataway et al. Studies on the iodination of a ras protein and the detection of ras polymers

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 514488

Country of ref document: ES